Keros Therapeutics is a biopharmaceutical company developing novel treatments for patients with hematological and musculoskeletal disorders. Its lead product candidate KER-050 is being developed for the treatment of cytopenias, including anemia and thrombocytopenia in patients suffering from myelodysplastic syndromes and myelofibrosis. The company's headquarters is located in Lexington, Massachusetts.